PURPOSE: To develop a sequencing assay for the gene to identify mutations in patients with cystic fibrosis (CF). METHODS: An automated assay format was developed to sequence all exons and splice junctional sequences, the promotor region, and parts of introns 11 and 19. RESULTS: After validating the assay using 20 known samples, DNA of seven patients, four of whom were heterozygous for a known CF mutation, was sequenced. Known CF mutations were detected in seven of the eight chromosomes, and a novel missense mutation was detected in the eighth. In addition, this assay allowed 14 ambiguous results obtained using the Roche CF gold strips to be resolved. Three false-positive diagnoses were prevented; a different mutation at the same codon was identified in two patients and confirmation was provided in the remaining nine cases. CONCLUSIONS: Sequencing of the gene provides important information for CF patients and is a valuable adjunct to a carrier screening program to resolve ambiguities in panel testing.
PURPOSE: To develop a sequencing assay for the gene to identify mutations in patients with cystic fibrosis (CF). METHODS: An automated assay format was developed to sequence all exons and splice junctional sequences, the promotor region, and parts of introns 11 and 19. RESULTS: After validating the assay using 20 known samples, DNA of seven patients, four of whom were heterozygous for a known CF mutation, was sequenced. Known CF mutations were detected in seven of the eight chromosomes, and a novel missense mutation was detected in the eighth. In addition, this assay allowed 14 ambiguous results obtained using the Roche CF gold strips to be resolved. Three false-positive diagnoses were prevented; a different mutation at the same codon was identified in two patients and confirmation was provided in the remaining nine cases. CONCLUSIONS: Sequencing of the gene provides important information for CF patients and is a valuable adjunct to a carrier screening program to resolve ambiguities in panel testing.
Authors: Margaret Lilley; Susan Christian; Stacey Hume; Patrick Scott; Mark Montgomery; Lisa Semple; Peter Zuberbuhler; Joan Tabak; Fiona Bamforth; Martin J Somerville Journal: Paediatr Child Health Date: 2010-11 Impact factor: 2.253
Authors: Andrew G Hadd; Walairat Laosinchai-Wolf; Chris R Novak; Marty R Badgett; Lesley A Isgur; Marianna Goldrick; Cindy R Walkerpeach Journal: J Mol Diagn Date: 2004-11 Impact factor: 5.568
Authors: Victoria M Pratt; Michele Caggana; Christina Bridges; Arlene M Buller; Lisa DiAntonio; W Edward Highsmith; Leonard M Holtegaard; Kasinathan Muralidharan; Elizabeth M Rohlfs; Jack Tarleton; Lorraine Toji; Shannon D Barker; Lisa V Kalman Journal: J Mol Diagn Date: 2009-04-09 Impact factor: 5.568
Authors: Karen M Schwartz; Lisa L Pike-Buchanan; Kasinathan Muralidharan; Joy B Redman; Jean Amos Wilson; Michael Jarvis; M Grace Cura; Victoria M Pratt Journal: J Mol Diagn Date: 2009-03-26 Impact factor: 5.568
Authors: Feras M Hantash; Joy B Redman; Kelsey Starn; Ben Anderson; Arlene Buller; Matthew J McGinniss; Franklin Quan; Mei Peng; Weimin Sun; Charles M Strom Journal: Hum Genet Date: 2005-12-17 Impact factor: 4.132
Authors: Matthew J McGinniss; Christina Chen; Joy B Redman; Arlene Buller; Franklin Quan; Mei Peng; Robert Giusti; Feras M Hantash; Donghui Huang; Weimin Sun; Charles M Strom Journal: Hum Genet Date: 2005-09-28 Impact factor: 4.132
Authors: David L Masica; Patrick R Sosnay; Karen S Raraigh; Garry R Cutting; Rachel Karchin Journal: Hum Mol Genet Date: 2014-12-08 Impact factor: 6.150
Authors: Danieli Barino Salinas; Colleen Azen; Suzanne Young; Thomas G Keens; Martin Kharrazi; Richard B Parad Journal: Genet Test Mol Biomarkers Date: 2016-07-22